These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38150674)

  • 1. SARS-CoV-2 reinfections in the pediatric cohort-a single-center experience.
    Arslan A; Sahbudak Bal Z; Erci E; Yıldırım Arslan S; Bilen NM; Avcu G; Çiçek C; Ozkinay F; Kurugol Z
    J Trop Pediatr; 2023 Dec; 70(1):. PubMed ID: 38150674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
    Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Reinfections in Health-Care Workers, 1 March 2020-31 January 2023.
    Cegolon L; Magnano G; Negro C; Larese Filon F;
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515237
    [No Abstract]   [Full Text] [Related]  

  • 4. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
    Shiwa-Sudo N; Sakai Y; Iwata-Yoshikawa N; Watanabe S; Yamada S; Kuroda Y; Yamamoto T; Shirakura M; Fujisaki S; Miyazaki K; Miura H; Nagata S; Fukushi S; Maeda K; Hasegawa H; Suzuki T; Nagata N
    J Virol; 2023 Jan; 97(1):e0136622. PubMed ID: 36633406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.
    Carazo S; Skowronski DM; Brisson M; Barkati S; Sauvageau C; Brousseau N; Gilca R; Fafard J; Talbot D; Ouakki M; Gilca V; Carignan A; Deceuninck G; De Wals P; De Serres G
    Lancet Infect Dis; 2023 Jan; 23(1):45-55. PubMed ID: 36152671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022.
    Vicentini M; Venturelli F; Mancuso P; Bisaccia E; Zerbini A; Massari M; Cossarizza A; De Biasi S; Pezzotti P; Bedeschi E; Giorgi Rossi P; ;
    Euro Surveill; 2023 Mar; 28(13):. PubMed ID: 36995374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prediction of protection probability against Omicron BA.1, BA.4 and BA.5 variants in symptomatic infections with prototype strain based on neutralization antibody levels].
    Lu WY; Chen XH; Zheng N; Yu HJ
    Zhonghua Yi Xue Za Zhi; 2023 May; 103(18):1429-1434. PubMed ID: 37150697
    [No Abstract]   [Full Text] [Related]  

  • 9. Trends in Laboratory-Confirmed SARS-CoV-2 Reinfections and Associated Hospitalizations and Deaths Among Adults Aged ≥18 Years - 18 U.S. Jurisdictions, September 2021-December 2022.
    Ma KC; Dorabawila V; León TM; Henry H; Johnson AG; Rosenberg E; Mansfield JA; Midgley CM; Plumb ID; Aiken J; Khanani QA; Auche S; Bayoumi NS; Bennett SA; Bernu C; Chang C; Como-Sabetti KJ; Cueto K; Cunningham S; Eddy M; Falender RA; Fleischauer A; Frank DM; Harrington P; Hoskins M; Howsare A; Ingaiza LM; Islam AS; Jensen SA; Jones JM; Kambach G; Kanishka F; Levin Y; Masarik JF; Meyer SD; Milroy L; Morris KJ; Olmstead J; Olsen NS; Omoike E; Patel K; Pettinger A; Pike MA; Reed IG; Slocum E; Sutton M; Tilakaratne BP; Vest H; Vostok J; Wang JS; Watson-Lewis L; Wienkes HN; Hagen MB; Silk BJ; Scobie HM
    MMWR Morb Mortal Wkly Rep; 2023 Jun; 72(25):683-689. PubMed ID: 37347715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico.
    Montes-González JA; Zaragoza-Jiménez CA; Antonio-Villa NE; Fermín-Martínez CA; Ramírez-García D; Vargas-Vázquez A; Gutiérrez-Vargas RI; García-Rodríguez G; López-Gatell H; Valdés-Ferrer SI; Bello-Chavolla OY
    Front Public Health; 2023; 11():1146059. PubMed ID: 37081954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune response and severity of Omicron BA.5 reinfection among individuals previously infected with different SARS-CoV-2 variants.
    Li L; Xie Z; Li Y; Luo M; Zhang L; Feng C; Tang G; Huang H; Hou R; Xu Y; Jia S; Shi J; Fan Q; Gan Q; Yu N; Hu F; Li Y; Lan Y; Tang X; Li F; Deng X
    Front Cell Infect Microbiol; 2023; 13():1277880. PubMed ID: 38188634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effect of previous infection and vaccination against reinfection with BA.5 Omicron subvariant: a nationwide population-based study in Japan.
    Kitamura N; Otani K; Kinoshita R; Yan F; Takizawa Y; Fukushima K; Yoneoka D; Suzuki M; Kamigaki T
    Lancet Reg Health West Pac; 2023 Dec; 41():100911. PubMed ID: 38223396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, Risk, and Severity of SARS-CoV-2 Reinfections in Children and Adolescents Between March 2020 and July 2022 in Serbia.
    Medic S; Anastassopoulou C; Lozanov-Crvenkovic Z; Dragnic N; Petrovic V; Ristic M; Pustahija T; Tsakris A; Ioannidis JPA
    JAMA Netw Open; 2023 Feb; 6(2):e2255779. PubMed ID: 36780157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and outcome of SARS-CoV-2 reinfection in the pre-Omicron era: A global systematic review and meta-analysis.
    Ismail NF; Rahman AE; Kulkarni D; Zhu F; Wang X; Del Carmen Morales G; Srivastava A; Allen KE; Spinardi J; Kyaw MH; Nair H
    J Glob Health; 2023 Nov; 13():06051. PubMed ID: 37994839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early SARS-CoV-2 Reinfections within 60 Days and Implications for Retesting Policies.
    Nevejan L; Cuypers L; Laenen L; Van Loo L; Vermeulen F; Wollants E; Van Hecke I; Desmet S; Lagrou K; Maes P; André E
    Emerg Infect Dis; 2022 Aug; 28(8):1729-1731. PubMed ID: 35738346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reinfection rate and disease severity of the BA.5 Omicron SARS-CoV-2 lineage compared to previously circulating variants of concern in the Canary Islands (Spain).
    Ciuffreda L; Lorenzo-Salazar JM; García-Martínez de Artola D; Gil-Campesino H; Alcoba-Florez J; Rodríguez-Pérez H; Íñigo-Campos A; Salas-Hernández J; Rodríguez-Nuñez J; Muñoz-Barrera A; Valenzuela-Fernández A; Díez-Gil O; González-Montelongo R; Flores C
    Emerg Microbes Infect; 2023 Dec; 12(1):2202281. PubMed ID: 37039029
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
    Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
    Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of symptoms, comorbidities, and reinfections in individuals infected with Wild-Type SARS-CoV-2, Delta, or Omicron variants: a comparative study in western Mexico.
    Peña Rodríguez M; Hernández Bello J; Vega Magaña N; Viera Segura O; García Chagollán M; Ceja Gálvez HR; Mora Mora JC; Rentería Flores FI; García González OP; Muñoz Valle JF
    Front Public Health; 2023; 11():1149795. PubMed ID: 37181688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.